Rituximab for autoimmune retinopathy: Results of a Phase I/II clinical trial
PURPOSE: This prospective study evaluates whether rituximab is a safe and potentially effective treatment for nonparaneoplastic autoimmune retinopathy (npAIR). MATERIALS AND METHODS: Five npAIR patients were enrolled in a Phase I/II, prospective, nonrandomized, open-label, single-center study. All p...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Taiwan Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.e-tjo.org/article.asp?issn=2211-5056;year=2021;volume=11;issue=1;spage=64;epage=70;aulast=Armbrust |